← Back to Search

Cohort B - no history of cSCC for Radiodermatitis

N/A

Recruiting

Led By Clara Curiel-Lewandrowski, MD

Research Sponsored by University of Arizona

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Individuals with moderate or severe photodamage of the skin on the forearms and Fitzpatrick skin type II or III

Individuals with a history of two or more cSCCs within the past 5 years or individuals with no history of cSCC

Timeline

Screening 3 weeks

Treatment Varies

Follow Up changes from baseline (pre-ssl exposure) to post-ssl exposure (at 24 hour post-exposure).

Awards & highlights

Study Summary

This trial is studying how people's skin changes when exposed to simulated sunlight. The researchers want to compare the skin of people who have had skin cancer to those who haven't, even if they have similar

Who is the study for?

This study is for people who have had skin cancer and those who haven't, but both groups should have similar skin types and sun exposure histories. Participants will undergo simulated sunlight exposure to their skin and must be willing to have small skin samples taken.Check my eligibility

What is being tested?

The trial aims to understand how proteins and genes in the skin respond to simulated sunlight. It involves exposing small areas of participants' skin to artificial light that mimics the sun's rays, followed by taking biopsies for analysis.See study design

What are the potential side effects?

Participants may experience mild to moderate sunburn-like effects or tanned spots where the simulated sunlight touches their skin. There might also be brief discomfort from injections of local anesthetic before biopsy procedures.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have moderate to severe sun damage on my forearms and have light to olive skin.

Select...

I have had two or more skin cancers in the past 5 years or none at all.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ changes from baseline (pre-ssl exposure) to post-ssl exposure (at 24 hour post-exposure).

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~changes from baseline (pre-ssl exposure) to post-ssl exposure (at 24 hour post-exposure).

This trial's timeline: 3 weeks for screening, Varies for treatment, and changes from baseline (pre-ssl exposure) to post-ssl exposure (at 24 hour post-exposure). for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

To assess PD-L1 protein expression levels in the epidermal keratinocytes of subjects with and without a history of cutaneous squamous cell skin cancer.

Secondary outcome measures

Evaluation of CD70/CD27 protein expression analysis

High dimensional data analysis

Spatial genomic assessment through whole transcriptomic analysis

Trial Design

2Treatment groups

Experimental Treatment

Group I: Cohort B - no history of cSCCExperimental Treatment1 Intervention

Participants without a history of squamous cell skin cancer (n=23) will be exposed to acute solar simulated light (SSL). Participants must have sun damage on the forearm, based on a standardized clinical photodamage scale (Hu C, Curiel-Lewandrowski C. Archives of Dermatology, 2011; 147(1):31-36). Each subject will act as his/her own control to minimize inter-subject variability.

Group II: Cohort A - history of > 2 Cutaneous squamous cell carcinoma (cSCC)Experimental Treatment1 Intervention

Participants who have a history of squamous cell skin cancer (n=23) will be exposed to acute solar simulated light (SSL). Participants must have sun damage on the forearm, based on a standardized clinical photodamage scale (Hu C, Curiel-Lewandrowski C. Archives of Dermatology, 2011; 147(1):31-36). Each subject will act as his/her own control to minimize inter-subject variability. Subjects from each cohort will be matched based on age and gender.

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of ArizonaLead Sponsor

515 Previous Clinical Trials

148,668 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,672 Previous Clinical Trials

40,926,395 Total Patients Enrolled

10 Trials studying Radiodermatitis

1,458 Patients Enrolled for Radiodermatitis

Clara Curiel-Lewandrowski, MDPrincipal InvestigatorUniversity of Arizona

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are researchers currently enrolling participants for this study?

"As per the information provided on clinicaltrials.gov, this trial is currently not seeking new participants. The trial was initially posted on January 1st, 2024 and its latest update occurred on December 11th, 2023. While this specific study is no longer enrolling patients, there are other ongoing studies that are actively accepting participants at present."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

SUV PDL1/PD1 in Sun Damaged & Sun Protected Human Skin of Participants

2023. "SUV PDL1/PD1 in Sun Damaged & Sun Protected Human Skin of Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06177106.

All > Tucson